DEFENSIN THERAPEUTICS ApS - CVR: 35513280

2023, DKK

30.05.2024

Bruttoresultat

Na.

Primær drift

-421'

Årets resultat

-425'

Aktiver

1.410'

Kortfristede aktiver

1.410'

Egenkapital

1.380'

Afkastningsgrad

-30 %

Soliditetsgrad

98 %

Likviditetsgrad

+500%

Resultat

30.05.2024

Årsrapport	2023 30.05.2024	2022 01.06.2023	2021 20.05.2022	2020 02.06.2021	2019 02.06.2020	2018 29.05.2019	2017 01.06.2018	2016 07.06.2017	2015 30.05.2016
Nettoomsætning			0				0	11.142.900
Resultat af primær drift	-421.297	-469.770	-343.323	-2.301.258	-1.833.772	-3.258.675	-2.286.588	7.420.923	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0	0
Finansielle indtægter	0	54	0	0	0	0	0	0	0
Finansieringsomkostninger	-4.047	-19.203	-26.948	-23.459	-18.881	-16.037	-31.281	-55.042	-750
Andre finansielle omkostninger	0	0	0	0	0	0	0	0	0
Resultat før skat	-425.344	-488.919	-370.271	-2.324.717	-1.852.653	-3.274.712	-2.317.869	7.365.881	-832.182
Resultat	-425.344	-473.890	-365.611	-2.315.678	-1.721.113	-2.952.934	-2.032.581	6.028.313	-811.429
Forslag til udbytte	0	0	0	0	0	0	0	0	0

Aktiver

30.05.2024

Årsrapport	2023 30.05.2024	2022 01.06.2023	2021 20.05.2022	2020 02.06.2021	2019 02.06.2020	2018 29.05.2019	2017 01.06.2018	2016 07.06.2017	2015 30.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	181.971	61.268	69.666	103.128	233.584	505.844	484.902	63.135	59.144
Likvider	1.227.684	1.703.770	2.110.021	2.595.522	4.808.097	610.066	3.633.914	7.673.467	183.265
Kortfristede aktiver	1.409.655	1.765.038	2.179.687	2.698.650	5.041.681	1.115.910	4.118.816	7.736.602	242.409
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0	0	4.668	4.532	7.160	0
Materielle aktiver	0	0	0	0	0	0	0	0	0
Langfristede aktiver	0	0	0	0	0	4.668	4.532	7.160	0
Aktiver	1.409.655	1.765.038	2.179.687	2.698.650	5.041.681	1.120.578	4.123.348	7.743.762	242.409

Aktiver

30.05.2024

Passiver

30.05.2024

Årsrapport	2023 30.05.2024	2022 01.06.2023	2021 20.05.2022	2020 02.06.2021	2019 02.06.2020	2018 29.05.2019	2017 01.06.2018	2016 07.06.2017	2015 30.05.2016
Forslag til udbytte	0	0	0	0	0	0	0	0	0
Egenkapital	1.380.154	1.667.999	2.141.889	2.507.500	4.823.177	1.029.591	3.942.399	5.974.979	-53.334
Hensatte forpligtelser	0	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0	0
Anden langfristet gæld		0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	29.501	97.039	32.798	170.850	198.904	71.249	138.539	335.906	83.772
Kortfristede forpligtelser	29.501	97.039	37.798	191.150	218.504	90.987	180.949	1.768.783	295.743
Gældsforpligtelser	0	0	0	0	0	0	0	0	295.743
Forpligtelser	0	0	0	0	0	0	0	0	295.743
Passiver	1.409.655	1.765.038	2.179.687	2.698.650	5.041.681	1.120.578	4.123.348	7.743.762	242.409

Passiver

30.05.2024

Nøgletal

30.05.2024

Årsrapport	2023 30.05.2024	2022 01.06.2023	2021 20.05.2022	2020 02.06.2021	2019 02.06.2020	2018 29.05.2019	2017 01.06.2018	2016 07.06.2017	2015 30.05.2016
Afkastningsgrad	-29,9 %	-26,6 %	-15,8 %	-85,3 %	-36,4 %	-290,8 %	-55,5 %	95,8 %	Na.
Dækningsgrad
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	54,1 %	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-30,8 %	-28,4 %	-17,1 %	-92,4 %	-35,7 %	-286,8 %	-51,6 %	100,9 %	1.521,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-10.410,1 %	-2.446,3 %	-1.274,0 %	-9.809,7 %	-9.712,3 %	-20.319,7 %	-7.309,8 %	13.482,3 %	Na.
Soliditestgrad	97,9 %	94,5 %	98,3 %	92,9 %	95,7 %	91,9 %	95,6 %	77,2 %	-22,0 %
Likviditetsgrad	4.778,3 %	1.818,9 %	5.766,7 %	1.411,8 %	2.307,4 %	1.226,4 %	2.276,2 %	437,4 %	82,0 %

Resultat

30.05.2024

Gæld

30.05.2024

Årsrapport

30.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 30.05.2024)

Information om virksomhedens regnskabsklasse:The annual report of Defensin Therapeutics ApS for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Oplysning om eventualaktiver:In April 2016, the Company signed a license and R&D agreement with Dr Falk Pharma GMBH (dated 15 April 2016) regarding the rights to develop, manufacture and market hBD-2 in Europe and Australia. The Danish and German Tax Authorities has not coordinated the taxation of the milestone payment received in 2016 from Dr Falk Pharma GMBH. The company has a pending claim with the Danish Tax Authorities to reimburse any double taxation on the transaction. Management has estimated the contingent asset to be DKK 289 thousand, however due to uncertainty regarding timing and amount, management has not recognized any tax receivable in the balance sheet at 31 December 2023. Defensin Therapeutics is entitled to receive potential royalties on successful commercialization of products developed under the asset sale and royaly agreement entered with Novonesis A/S. Since the size and timing of such payments are uncertain until sales are generated, these payments qualify as contingent assets.

Beretning

30.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-15

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Defensin Therapeutics ApS for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Defensin Therapeutics (DT) is a Danish biopharmaceutical company incorporated 6 October 2013 as a spin out from Novozymes A/S of the human defensin development program. Novozymes A/S and Christian Hansen Holding A/S have merged as of February 1st 2024. The new company is called Novonesis A/S. In April 2016, the Company signed a license and R&D agreement with Dr Falk Pharma GMBH (dated 15 April 2016) regarding the rights to develop, manufacture and market hBD-2 in Europe and Australia. In connection with the completion of the agreement, the Company received a non-refundable upfront payment of EUR 1. 5m in 2016. The production of hBD-2 has turned out to be more complicated than originally thought and Falk has thus decided to terminate the agreement as per March 12th 2020. On June 16th 2021, the company signed a “patent purchase and license back agreement” with Novonesis A/S. Novonesis A/S has purchased all DT patent rights except the patent application “Prevention and treatment of graft-versus-host-disease with defensins”. DT has however retained a royalty-free, exclusive, worldwide, non-transferable, sub-licensable and assignable license to the patent rights within ethical pharmaceuticals. The company has received a non-refundable payment of DKK 400,000 in 2021.